Intro Widget

Gut is a leading international journal in gastroenterology and hepatology and has an established reputation for publishing first class clinical research of the alimentary tract, the liver, biliary tree and pancreas. Gut delivers up-to-date, authoritative, clinically oriented coverage in all areas of gastroenterology and hepatology. Regular features include articles by leading authorities describing novel mechanisms of disease and new management strategies, both diagnostic and therapeutic, likely to impact on clinical practice within the foreseeable future.

Gut is an official journal of the British Society of Gastroenterology.

Editor-in-Chief: Professor Emad El-Omar, University of New South Wales, Sydney, Australia
Editorial Board

TOP CITED ARTICLES
Read the most-cited articles from the past three years for free here.

MEDIA NEWS
Read our latest press-released articles:
Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years
Yogurt consumption and risk of conventional and serrated precursors of colorectal cancer

SOCIAL MEDIA AND MULTIMEDIA
Keep up-to-date with Gut on Twitter and Facebook, and access videos on our YouTube channel.

Podcast iconGut publishes podcasts discussing highlights from its issues. Subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

Impact Factor
17.943

Authors

The Author Information section provides specific article requirements to help you turn your research into an article suitable for Gut.
 
Information is also provided on editorial policies and open access.

Impact Factor
17.943

Twitter Feed

Altmetrics

Featured Article

Featured Video

A blood-based prognostic biomarker in inflammatory bowel disease

To cite: Biasci D, Lee JC, Noor NM, et al. Gut 2019;68:1386-1395.

Read the full article here: link
Objective: We have previously described a prognostic transcriptional signature in CD8 T cells that separates patients with IBD into two phenotypically distinct subgroups, termed IBD1 and IBD2. Here we sought to develop a blood-based test that could identify these subgroups without cell separation, and thus be suitable for clinical use in Crohn’s disease (CD) and ulcerative colitis (UC).

Conclusion: This is the first validated prognostic biomarker that can predict prognosis in newly diagnosed patients with IBD and represents a step towards personalised therapy.

Related Content